BEBT-109

N/A

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameBEBT-109
Drug Alias NameBEBT-109
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitorsEGFR exon 20 insertion mutations inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1EGFR T790MEGFR exon 20 insertion mutations
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGuangzhou BeBetter Medicine Technology Co
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou BeBetter Medicine Technology Co
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A